Mario Ágreda Fernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mario Ágreda Fernández has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Isabel Rodríguez-Goncer
Unit of Infectious Diseases Hospital Universitario “12 de Octubre” Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12) Madrid Spain
2 shared publications - José María Aguado
Unit of Infectious Diseases Hospital Universitario “12 de Octubre” Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12) Madrid Spain
2 shared publications - Mario Fernández-Ruiz
Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12), Madrid, Spain
2 shared publications - Francisco López-Medrano
Unit of Infectious Diseases, University Hospital ‘12 de Octubre’, Madrid, Spain
1 shared publication Julia Origüen
Unit of Infectious Diseases University Hospital "12 de Octubre" Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12) Madrid Spain
1 shared publication- Julia Origüen
Department of Infectious Diseases, Hospital Universitario “12 de Octubre,” Madrid
1 shared publication
Latest Publications
- 11 December 2023
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (2) , 313-324
Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection
Purpose We investigated the role of fecal calprotectin (FC) and lactoferrin (FL) as predictive biomarkers in Clostridioides difficile infection (CDI). Methods We assembled a prospective cohort including all patients with a laboratory-confirmed CDI diagnosis between January and December 2017. FL and FC levels were measured at diagnosis by commercial ELISA and EIA kits. We investigated the diagnostic accuracy of FC and FL to predict CDI recurrence and severity (study outcomes) and explored optimal cut-off values in addition to those proposed by the manufacturers (200 µg/g and 7.2 µg/mL, respectively). Results We included 170 CDI cases (152 first episodes and 18 recurrences). The rates of recurrence (first episodes only) and severity (entire cohort) were 9.2% (14/152) and 46.5% (79/170). Both FL and FC levels were significantly higher in patients who developed study outcomes. Optimal cut-off values for FC and FL to predict CDI recurrence were 1052 µg/g and 6.0 µg/mL. The optimal cut-off value for FC yielded higher specificity (60.9%) and positive predictive value (PPV) (16.9%) than that proposed by the manufacturer. Regarding CDI severity, the optimal cut-off value for FC (439 µg/g) also provided higher specificity (43.9%) and PPV (54.1%) than that of the manufacturer, whereas the optimal cut-off value for FL (4.6 µg/mL) resulted in an improvement of PPV (57.5%). Conclusion By modifying the thresholds for assay positivity, the measurement of FC and FL at diagnosis is useful to predict recurrence and severity in CDI. Adding these biomarkers to current clinical scores may help to individualize CDI management.
- 11 December 2023
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (2) , 313-324
Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection
Purpose We investigated the role of fecal calprotectin (FC) and lactoferrin (FL) as predictive biomarkers in Clostridioides difficile infection (CDI). Methods We assembled a prospective cohort including all patients with a laboratory-confirmed CDI diagnosis between January and December 2017. FL and FC levels were measured at diagnosis by commercial ELISA and EIA kits. We investigated the diagnostic accuracy of FC and FL to predict CDI recurrence and severity (study outcomes) and explored optimal cut-off values in addition to those proposed by the manufacturers (200 µg/g and 7.2 µg/mL, respectively). Results We included 170 CDI cases (152 first episodes and 18 recurrences). The rates of recurrence (first episodes only) and severity (entire cohort) were 9.2% (14/152) and 46.5% (79/170). Both FL and FC levels were significantly higher in patients who developed study outcomes. Optimal cut-off values for FC and FL to predict CDI recurrence were 1052 µg/g and 6.0 µg/mL. The optimal cut-off value for FC yielded higher specificity (60.9%) and positive predictive value (PPV) (16.9%) than that proposed by the manufacturer. Regarding CDI severity, the optimal cut-off value for FC (439 µg/g) also provided higher specificity (43.9%) and PPV (54.1%) than that of the manufacturer, whereas the optimal cut-off value for FL (4.6 µg/mL) resulted in an improvement of PPV (57.5%). Conclusion By modifying the thresholds for assay positivity, the measurement of FC and FL at diagnosis is useful to predict recurrence and severity in CDI. Adding these biomarkers to current clinical scores may help to individualize CDI management.